SFROWASA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sfrowasa, and when can generic versions of Sfrowasa launch?
Sfrowasa is a drug marketed by Mylan Speciality Lp and is included in one NDA. There is one patent protecting this drug.
This drug has seven patent family members in seven countries.
The generic ingredient in SFROWASA is mesalamine. There are twenty-eight drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the mesalamine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sfrowasa
A generic version of SFROWASA was approved as mesalamine by PADAGIS ISRAEL on September 17th, 2004.
Summary for SFROWASA
| International Patents: | 7 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 181 |
| Patent Applications: | 4,123 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for SFROWASA |
| What excipients (inactive ingredients) are in SFROWASA? | SFROWASA excipients list |
| DailyMed Link: | SFROWASA at DailyMed |
Pharmacology for SFROWASA
| Drug Class | Aminosalicylate |
US Patents and Regulatory Information for SFROWASA
SFROWASA is protected by one US patents.
Patents protecting SFROWASA
Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Speciality Lp | SFROWASA | mesalamine | ENEMA;RECTAL | 019618-002 | Jun 20, 2008 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SFROWASA
See the table below for patents covering SFROWASA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Israel | 81799 | PACKAGED PHARMACEUTICAL COMPOSITION CONTAINING BISULFITE STABILIZED SOLUTION OF 5-AMINOSALICYCLIC ACID AND METHODS FOR THE PREPARATION THEREOF | ⤷ Try a Trial |
| Spain | 2026179 | ⤷ Try a Trial | |
| Canada | 1230056 | SOLUTION OU SUSPENSION STABLE CONTENANT DE L'ACIDE 5-AMINOSALICYLIQUE POUR LES LAVEMENTS (PACKAGED STABLE ENEMA SOLUTION OR SUSPENSION CONTAINING 5-AMINOSALICYCLIC ACID) | ⤷ Try a Trial |
| European Patent Office | 2107870 | LAVEMENT À EFFET IRRITANT RÉDUIT DESTINÉ AU TRAITEMENT D'UNE AFFECTION INTESTINALE INFLAMMATOIRE (IBD) (REDUCED IRRITANT ENEMA FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD)) | ⤷ Try a Trial |
| Australia | 2008211124 | Improved reduced irritant enema for the treatment of Inflammatory Bowel Disease (IBD) | ⤷ Try a Trial |
| European Patent Office | 0279093 | CONTAINER FOR A STABILIZED AQUEOUS SOLUTION OF 5-AMINOSALICYLIC ACID | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
